FDA Brief

Warning letters Drugs

FDA warning letter to

Chengdu Innovation Pharmaceutical Co., Ltd.

High riskIssued Feb 5, 2025Posted Feb 11, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.

What happened

FDA reviewed records Chengdu Innovation submitted after an April 29, 2024 request for records under section 704(a)(4). It found the company did not test the identity of each lot of incoming production material before release and its quality unit did not set up a system to approve or reject incoming materials. FDA placed the firm’s products on Import Alert 66-40 (a list that blocks imports) on January 17, 2025.

What FDA found

  1. The company did not test the identity of each lot of incoming production material before releasing it for use.

  2. The quality unit did not establish a system to approve or reject raw materials, intermediates, packaging, and labeling materials.

  3. FDA said the APIs are adulterated because the firm’s methods, facilities, or controls do not conform to CGMP.

    FD&C Act section 501(a)(2)(B)

What FDA wants

FDA tells the company to respond in writing within 30 working days with corrective actions and steps to prevent recurrence, including plans to test incoming material identity and strengthen quality unit oversight. If it cannot complete corrective actions within 15 working days, it must state why and give a completion schedule.

Who should pay attention

  • drugmakers that use this firm's APIs
  • companies relying on supplier certificates of analysis
  • US applicants listing this site as an API manufacturer

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk